132 related articles for article (PubMed ID: 38231013)
1. Successful treatment of cutaneous-onset Erdheim-Chester disease with cobimetinib and anakinra.
Aromolo IF; Moltrasio C; Maronese CA; Campochiaro C; Bonometti A; Berti E; Passoni E; Marzano A
Clin Exp Dermatol; 2024 Apr; 49(5):523-525. PubMed ID: 38231013
[No Abstract] [Full Text] [Related]
2. Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein.
Courcoul A; Vignot E; Chapurlat R
Joint Bone Spine; 2014 Mar; 81(2):175-7. PubMed ID: 23953221
[TBL] [Abstract][Full Text] [Related]
3. Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib.
Schirmer JH; Thorns C; Moosig F; Holle JU
Rheumatology (Oxford); 2015 Oct; 54(10):1932-4. PubMed ID: 26139656
[No Abstract] [Full Text] [Related]
4. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.
Cohen Aubart F; Emile JF; Maksud P; Galanaud D; Cluzel P; Benameur N; Aumaitre O; Amoura Z; Haroche J
Br J Haematol; 2018 Jan; 180(1):150-153. PubMed ID: 27711968
[No Abstract] [Full Text] [Related]
5. Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra.
Aubert O; Aouba A; Deshayes S; Georgin-Lavialle S; Rieu P; Hermine O
Joint Bone Spine; 2013 Mar; 80(2):206-7. PubMed ID: 22999905
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of five years of treatment of Erdheim-Chester disease with anakinra: case report and overview of literature].
Adam Z; Petrášová H; Řehák Z; Koukalová R; Krejčí M; Pour L; Vetešníková E; Čermák A; Ševčíková S; Szturz P; Král Z; Mayer J
Vnitr Lek; 2016; 62(10):820-832. PubMed ID: 27900869
[TBL] [Abstract][Full Text] [Related]
7. Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs.
Tran TA; Pariente D; Lecron JC; Delwail A; Taoufik Y; Meinzer U
Arthritis Rheum; 2011 Dec; 63(12):4031-2. PubMed ID: 21898344
[No Abstract] [Full Text] [Related]
8. Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma.
Cohen PR; Kurzrock R
Dermatol Online J; 2014 Jan; 20(1):21241. PubMed ID: 24456945
[TBL] [Abstract][Full Text] [Related]
9. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease.
Cohen-Aubart F; Maksud P; Saadoun D; Drier A; Charlotte F; Cluzel P; Amoura Z; Haroche J
Blood; 2016 Mar; 127(11):1509-12. PubMed ID: 26847247
[No Abstract] [Full Text] [Related]
10. Erdheim-Chester disease with cardiac involvement successfully treated with anakinra.
Killu AM; Liang JJ; Jaffe AS
Int J Cardiol; 2013 Sep; 167(5):e115-7. PubMed ID: 23659884
[No Abstract] [Full Text] [Related]
11. Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids.
Darstein F; Kirschey S; Heckl S; Rahman F; Schwarting A; Schuchmann M; Galle PR; Zimmermann T
Intern Med J; 2014 Jan; 44(1):90-2. PubMed ID: 24450524
[TBL] [Abstract][Full Text] [Related]
12. The "hairy kidney" sign.
Triffo WJ; Dyer RB
Abdom Radiol (NY); 2017 Mar; 42(3):979-980. PubMed ID: 27841012
[No Abstract] [Full Text] [Related]
13. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).
Cohen Aubart F; Emile JF; Carrat F; Charlotte F; Benameur N; Donadieu J; Maksud P; Idbaih A; Barete S; Hoang-Xuan K; Amoura Z; Haroche J
Blood; 2017 Sep; 130(11):1377-1380. PubMed ID: 28667012
[No Abstract] [Full Text] [Related]
14. Erdheim-Chester disease presenting as periodontal disease: Experience of treatment with cladribine, interferon-a, local radiotherapy and anakinra.
Blomstrand L; Thor A; Hagberg H
Acta Oncol; 2016; 55(2):248-50. PubMed ID: 25902723
[No Abstract] [Full Text] [Related]
15. Efficacy of infliximab in the treatment of Erdheim-Chester disease.
Cohen-Aubart F; Maksud P; Emile JF; Benameur N; Charlotte F; Cluzel P; Amoura Z; Haroche J
Ann Rheum Dis; 2018 Sep; 77(9):1387-1390. PubMed ID: 29363511
[No Abstract] [Full Text] [Related]
16. Impact of anakinra treatment on cytokine and lymphocytes/ monocytes profile of an Erdheim-Chester patient.
Sevčíková S; Kubiczková L; Sedlaříková L; Ríhová L; Kryukov F; Szturz P; Hajek R; Pour L; Adam Z
Klin Onkol; 2014; 27(4):276-82. PubMed ID: 25115717
[TBL] [Abstract][Full Text] [Related]
17. Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease.
Tomelleri A; Cavalli G; De Luca G; Campochiaro C; D'Aliberti T; Tresoldi M; Dagna L
Front Immunol; 2018; 9():1233. PubMed ID: 29910817
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of biological agents in the treatment of Erdheim-Chester disease.
Goyal G; Shah MV; Call TG; Litzow MR; Wolanskyj-Spinner AP; Koster MJ; Tobin WO; Vassallo R; Ryu JH; Hook CC; Hogan WJ; Go RS
Br J Haematol; 2018 Nov; 183(3):520-524. PubMed ID: 29082516
[No Abstract] [Full Text] [Related]
19. [Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease - case study and a review of literature].
Adam Z; Szturz P; Bučková P; Cervinková I; Koukalová R; Rehák Z; Krejčí M; Pour L; Zahradová L; Hájek R; Král Z; Mayer J
Vnitr Lek; 2012 Apr; 58(4):313-8. PubMed ID: 22559807
[TBL] [Abstract][Full Text] [Related]
20. [Use of targeting therapy in Erdheim-Chester disease: A case report with neurologic involvement].
Berthe P; Rouzic N; Daelman L; Jacobzone C; Espitia A; Cohen-Aubart F; Haroche J; Émile JF; Lorleac'h A
Rev Med Interne; 2020 Jun; 41(6):413-417. PubMed ID: 32113636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
